COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Efficacy and Safety Study of Ataciguat Versus Placebo in Patients With Neuropathic Pain (SERENEATI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00799656
Recruitment Status : Completed
First Posted : December 1, 2008
Last Update Posted : April 1, 2011
Information provided by:

Brief Summary:

The primary objective of this study is to assess the efficacy of ataciguat versus placebo in reducing pain intensity in patients with neuropathic pain.

The secondary objective is to assess the safety and tolerability of ataciguat versus placebo.

Condition or disease Intervention/treatment Phase
Pain Drug: ataciguat (HMR1766) Drug: placebo Phase 2

Detailed Description:
This study consists of two consecutive 28 day treatment periods which are separated by a 2 week medication free period and a safety follow-up period of 2 weeks after the second treatment period.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 62 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Efficacy and Safety of Oral Ataciguat (HMR1766) 200 mg Administered Once Daily for 28 Days on Pain Reduction in Patients With Neuropathic Pain. A Randomized, Double-blind, Placebo-controlled, Cross-over Study
Study Start Date : November 2008
Actual Primary Completion Date : June 2009
Actual Study Completion Date : September 2009

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: 1
First period: Ataciguat - Second period: Placebo
Drug: ataciguat (HMR1766)
oral administration 200mg once daily for 28 days

Drug: placebo
oral administration once daily for 28 days

Experimental: 2
First period: Placebo - Second period: Ataciguat
Drug: ataciguat (HMR1766)
oral administration 200mg once daily for 28 days

Drug: placebo
oral administration once daily for 28 days

Primary Outcome Measures :
  1. Change in average daily pain intensity [ Time Frame: after 28-days treatment ]

Secondary Outcome Measures :
  1. Responder rate [ Time Frame: after 28-days treatment ]
  2. Rescue medication intake [ Time Frame: during 28-days treatment ]
  3. Change in Neuropathic Pain Symptom Inventory (NPSI) [ Time Frame: after 28-days treatment ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with chronic neuropathic pain due to diabetic polyneuropathy or a nerve lesion following surgery. The pain must be present for more than 3 months.

Exclusion Criteria:

  • Presence or history of cancer within the past five years
  • Patients with a history of HIV infection
  • Patients with active hepatitis B or C
  • Patients with any pain other than the neuropathic pain of greater or equal severity
  • Patients with a diabetes mellitus for less than 6 months

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00799656

Layout table for location information
Sanofi-Aventis Administrative Office
Wien, Austria
Czech Republic
Sanofi-Aventis Administrative Office
Praha, Czech Republic
Sanofi-Aventis Administrative Office
Bucuresti, Romania
Sponsors and Collaborators
Layout table for investigator information
Principal Investigator: Hans-Goerg Kress, Professor Medizinische Universität / AKH Wien - Währinger Gürtel 18-20 - A-1090 Wien
Layout table for additonal information
Responsible Party: ICD Study Director, sanofi-aventis Identifier: NCT00799656    
Other Study ID Numbers: DFI10569
EudraCT 2008-001518-26
First Posted: December 1, 2008    Key Record Dates
Last Update Posted: April 1, 2011
Last Verified: March 2011
Keywords provided by Sanofi:
Diabetic neuropathy
painful pain
Additional relevant MeSH terms:
Layout table for MeSH terms
Peripheral Nervous System Diseases
Neuromuscular Diseases
Nervous System Diseases
Neurologic Manifestations
Enzyme Activators
Molecular Mechanisms of Pharmacological Action